<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03606746</url>
  </required_header>
  <id_info>
    <org_study_id>MDR-103-L2K</org_study_id>
    <nct_id>NCT03606746</nct_id>
  </id_info>
  <brief_title>Cellular Immunotherapy for Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kidney Transplants</brief_title>
  <official_title>A Phase 2 Prospective, Multi-center, Open-label Trial to Assess the Safety &amp; Efficacy of Cellular Immunotherapy With MDR-103 for Induction of Mixed Chimerism &amp; Immune Tolerance in Past Recipients of HLA Zero-mismatch, LD Kidney Transplants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medeor Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medeor Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate the safety and efficacy of cellular&#xD;
      immunotherapy with MDR-103 for induction of functional immune tolerance in past recipients of&#xD;
      human leukocyte antigen (HLA)-matched, living donor kidney transplants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, patients receiving a transplanted kidney are required to take life-long&#xD;
      immunosuppressive medications to prevent rejection of the transplanted kidney. These&#xD;
      medications carry substantial side effects. In addition, these medicines often do not&#xD;
      completely control damage to the kidney from the recipients' immune system, ultimately&#xD;
      causing the kidney to fail.&#xD;
&#xD;
      Medeor Therapeutics is developing a novel cell-based therapy to reprogram the past&#xD;
      recipients' immune system to accept the transplanted kidney without the concurrent need for&#xD;
      long term use of immunosuppressive drugs.&#xD;
&#xD;
      The purpose of the current Phase 2 study is to demonstrate the efficacy and safety of MDR-103&#xD;
      for the induction of transplant immune tolerance in a prospective, multicenter clinical&#xD;
      trial. MDR-103 is intended to induce mixed lymphohematopoietic chimerism and donor specific&#xD;
      immune tolerance in order to preserve transplant kidney function, avert transplant kidney&#xD;
      rejection, and eliminate the cumulative and serious side effects associated with&#xD;
      immunosuppressive drugs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Persistent Mixed Chimerism</measure>
    <time_frame>At 6 months post initiation of anti-thymocyte globulin (ATG) conditioning therapy</time_frame>
    <description>The primary efficacy endpoint is the proportion of subjects achieving persistent mixed chimerism in MDR-103 treated recipients of past HLA zero-mismatch living donor kidney transplants.&#xD;
Persistent Mixed Chimerism - is defined as at least 6 months of persistent WBC mixed chimerism consisting of at least 5% donor cells in whole blood or in at least one WBC lineage (CD3+ T cells, CD33+ myeloid cells, CD19+ B cells, and/or CD56+ NK cells).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Kidney Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Investigational Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A low-dose Total Lymphoid Irradiation (TLI) and anti-thymocyte globulin (ATG) combined with a single IV infusion of MDR-103 and standard anti-rejection medications in past recipients of HLA Zero-mismatch living donor kidney transplants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MDR-103</intervention_name>
    <description>MDR-103 Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells</description>
    <arm_group_label>Investigational Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Recipient Inclusion Criteria:&#xD;
&#xD;
          -  Past recipient of a first kidney allograft from an HLA-matched, living related donor&#xD;
&#xD;
          -  Age ≥18 and ≤70 years&#xD;
&#xD;
          -  Single solid organ recipient (kidney only)&#xD;
&#xD;
          -  ABO compatibility with donor&#xD;
&#xD;
        Donor Inclusion Criteria:&#xD;
&#xD;
          -  HLA-matched first degree (parent, child or sibling) or second-degree (child of a&#xD;
             sibling, half sibling) relative of the prospective recipient participant&#xD;
&#xD;
          -  Age ≥18 and ≤70 years&#xD;
&#xD;
          -  Past living related kidney donor, and capable of undergoing G-CSF mobilization and&#xD;
             apheresis of hematopoietic cells&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Recipient Exclusion Criteria:&#xD;
&#xD;
          -  Underlying kidney disease with a high risk of disease recurrence in the transplanted&#xD;
             kidney&#xD;
&#xD;
          -  Baseline positive donor-specific anti-HLA antibody testing&#xD;
&#xD;
          -  Is taking immunosuppressive therapy&#xD;
&#xD;
          -  Evidence of prior hepatitis B (HBV) or hepatitis C (HCV)&#xD;
&#xD;
        Donor Exclusion Criteria:&#xD;
&#xD;
          -  History of autoimmune disorders&#xD;
&#xD;
          -  History of type 1 or type 2 diabetes mellitus&#xD;
&#xD;
          -  Tests confirmed positive for human immunodeficiency virus (HIV), HBV, HCV&#xD;
&#xD;
          -  History of infection with Zika virus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanne Crowley, MS, BSN</last_name>
    <role>Study Director</role>
    <affiliation>Medeor Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lenuta Micsa, MD</last_name>
    <phone>646-239-9748</phone>
    <email>lmicsa@medeortx.com</email>
  </overall_contact>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 20, 2018</study_first_submitted>
  <study_first_submitted_qc>July 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Transplant</keyword>
  <keyword>Kidney Failure</keyword>
  <keyword>Anti-rejection therapy</keyword>
  <keyword>Living Donor</keyword>
  <keyword>HLA-matched</keyword>
  <keyword>Hematopoietic Stem Cells (HSC)</keyword>
  <keyword>CD34+</keyword>
  <keyword>CD3+</keyword>
  <keyword>T cells</keyword>
  <keyword>Cellular Therapy</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Immunosuppression</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

